Alnylam Pharmaceuticals’ (ALNY) “Buy” Rating Reaffirmed at B. Riley

B. Riley reaffirmed their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note released on Friday morning. The brokerage currently has a $205.00 target price on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on ALNY. Sanford C. Bernstein reaffirmed a buy rating and issued a $135.00 price target (up previously from $94.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 21st. Ladenburg Thalmann Financial Services reaffirmed a buy rating and issued a $146.00 price target (up previously from $90.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 21st. BMO Capital Markets reaffirmed an outperform rating and issued a $134.00 price target (up previously from $99.00) on shares of Alnylam Pharmaceuticals in a report on Friday, September 22nd. Chardan Capital reaffirmed a buy rating and issued a $124.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, September 25th. Finally, Jefferies Group upped their target price on shares of Alnylam Pharmaceuticals from $102.00 to $130.00 and gave the stock a buy rating in a research report on Tuesday, September 26th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Alnylam Pharmaceuticals presently has an average rating of Buy and an average price target of $121.20.

Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at $131.00 on Friday. The firm has a market cap of $12,880.00, a price-to-earnings ratio of -24.95 and a beta of 2.98. Alnylam Pharmaceuticals has a 1-year low of $35.98 and a 1-year high of $147.63. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 9.83.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.11). The firm had revenue of $17.10 million during the quarter, compared to the consensus estimate of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The company’s revenue for the quarter was up 24.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.21) EPS. research analysts expect that Alnylam Pharmaceuticals will post -5.29 EPS for the current year.

In other Alnylam Pharmaceuticals news, EVP Akshay Vaishnaw sold 33,666 shares of the company’s stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $121.46, for a total transaction of $4,089,072.36. Following the completion of the sale, the executive vice president now directly owns 45,201 shares in the company, valued at $5,490,113.46. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Laurie Keating sold 6,249 shares of the company’s stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total transaction of $757,378.80. Following the sale, the senior vice president now owns 17,749 shares of the company’s stock, valued at $2,151,178.80. The disclosure for this sale can be found here. Insiders sold 274,075 shares of company stock valued at $35,356,089 over the last quarter. 4.30% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of ALNY. FMR LLC boosted its position in Alnylam Pharmaceuticals by 6.3% during the second quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock valued at $1,094,559,000 after buying an additional 815,270 shares during the period. Vanguard Group Inc. boosted its position in Alnylam Pharmaceuticals by 13.4% during the second quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock valued at $512,020,000 after buying an additional 759,295 shares during the period. Janus Henderson Group PLC purchased a new stake in Alnylam Pharmaceuticals during the second quarter valued at about $53,226,000. Orbimed Advisors LLC boosted its position in Alnylam Pharmaceuticals by 69.7% during the third quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock valued at $127,453,000 after buying an additional 445,600 shares during the period. Finally, BlackRock Inc. boosted its position in Alnylam Pharmaceuticals by 9.3% during the second quarter. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company’s stock valued at $413,811,000 after buying an additional 441,957 shares during the period. Institutional investors and hedge funds own 88.41% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Alnylam Pharmaceuticals’ (ALNY) “Buy” Rating Reaffirmed at B. Riley” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://ledgergazette.com/2018/01/23/alnylam-pharmaceuticals-alny-buy-rating-reaffirmed-at-b-riley-2.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply